Skip to content
Kalpvruksh Markets
Offline Log in

GKSLNSEOffline

GUJ. KIDNEY & SUPER · INE0V0W01025 · Small Cap · #1482
158.21−1.50 (−0.94%)last close · 05 Nov 2026
Prev close
159.71
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹916 cr
52-week range · to 05 Nov 202699.36194.69

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

GKSL is 19% below its 52-week high, above its 200-day average — a Small Cap company, #1482 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 200-day average · below its 20 / 50-day averages · 19% below its 52-week high
  • +20.2% vs Nifty 500
  • traded value 1.0× usual · delivery 42% vs 42% usual
  • FPI +1.6 pp · DII −0.3 pp · MF schemes in Sept 2026: 1 bought, 0 cut · no promoter pledge · quarter ended 2026-09-30
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹916 cr
Rank
#1482
Cap band
Small Cap
Nearest cut-off — Mid / Small
−97.32% from ₹34,190 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
1.8×
median 2,40,448
Delivered
4,35,223
Of volume
39%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week−7.9%−13.0 pts—
1 month−18.3%−21.9 pts—
3 months+17.6%+20.2 pts—
6 months+27.9%+27.4 pts—
1 year———

Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
−10.5%
below
vs 50-day average
−9.5%
below
vs 200-day average
+17.3%
above
ATR (14)
4.0%
typical daily range
Volatility
47%
1 month, annualised
Beta
0.45
vs Nifty 500, 1 year
Traded value
1.0×
vs usual
Delivery
42%
usual 42%
From the 52-week high
−18.7%
place in range 62% (0 = at the low)

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters71.5%71.5%71.5%71.5%
FPI10.5%4.9% −5.64.9%6.5% +1.6
Mutual funds————
Other DII1.7%0.6% −1.10.6%0.3% −0.3
Individuals11.6%10.6% −0.910.6%9.5% −1.1
Others4.8%12.5% +7.612.5%12.3% −0.2

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Sep 25 noneDec 25 noneMar 26 noneJun 26 noneSep 26 none

Holders

Sep 26

All shareholders
12,986
Individuals
12,649

Indian passive funds’ stake

2026-06-30

Of free float
0.00%
Of all shares
0.00%
Schemes
2
Days to unwind
<0.1
at 100% of volume

895 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
2
2 index · 0 active
Bought more
2
Sold some
0

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 2610100+1.5%₹0 cr
Aug 2610100+0.2%₹0 cr
Jul 2610100+2.2%₹0 cr
Jun 2610100+64.0%₹0 cr
May 2610010−9.5%₹0 cr
Apr 2610010−3.9%₹0 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Disclosures & deals

last six months · NSE filings

  • Board outcome
    Gujarat Kidney And Super Speciality Limited has submitted to the Exchange, the unaudited Standalone and Consolidated financial results for the period ended September 30, 2026.
    05 Nov 2026
  • Board outcome
    Gujarat Kidney And Super Speciality Limited has informed the Exchange regarding Outcome of Board Meeting held on August 24, 2026.
    25 Aug 2026
  • Board outcome
    Gujarat Kidney And Super Speciality Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
    17 Aug 2026
  • Scheme / acquisition
    Acquisition (including agreement to acquire)-XBRL GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED has informed the Exchange regarding Acquisition (including agreement to acquire)
    10 Jul 2026
  • Scheme / acquisition
    Gujarat Kidney And Super Speciality Limited has informed the Exchange about Acquisition of 51% of Blue Tree Clinics LLC
    10 Jul 2026
  • Board outcome
    Gujarat Kidney And Super Speciality Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
    29 May 2026
  • Bulk deal: SELL
    4,38,656 at ₹178 — NEXUS GLOBAL OPPORTUNITIES FUND
    26 Oct 2026
  • Bulk deal: BUY
    4,71,148 at ₹188.97 — NATVARSINH T CHAVDA
    07 Oct 2026
  • Bulk deal: SELL
    4,86,148 at ₹192.19 — NATVARSINH T CHAVDA
    07 Oct 2026
  • Bulk deal: BUY
    7,21,367 at ₹189.1 — NATVARSINH T CHAVDA
    05 Oct 2026

Latest shown; 11 in six months on all disclosures.

GKSL: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.